^
    Back
    Association details:
    Biomarker:NOTCH1 positive + FGFR2 mutation
    Cancer:Adenoid Cystic Carcinoma
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) +
    Balversa (erdafitinib) (pan-FGFR inhib)
    Drug Class:γ-secretase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2021
    Title:

    Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors

    Published date:
    05/19/2021
    Excerpt:
    One patient with primary lacrimal gland ACC metastatic to the liver and tNGS positive for NOTCH 1 had disease progression despite treatment with Lenvatinib and a NOTCH γ-secretase inhibitor. The patient’s ctDNA reported a FGFR2 mutation. The patient was started on Erdafitinib, an oral selective FGFR inhibitor, achieving a partial response at the primary site and metastatic liver lesions and remained on therapy for 7 months.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e15018